Navigation Links
Gene-Transfer Proves Safe for Vision Problem
Date:9/12/2008

Volunteers with rare eye disease regained partial sight with experimental therapy

FRIDAY, Sept. 12 (HealthDay News) -- Three people with a rare, incurable form of hereditary blindness regained some sight after receiving experimental gene therapy, a new report says.

The patients, all in their early 20s, have Leber congenital amaurosis type 2 (LCA2), a disease in which photoreceptor cells cannot respond to light, because a gene called RPE65 does not properly produce a protein necessary for healthy vision.

In the study, published online in Human Gene Therapy, researchers at the University of Florida used an adeno-associated virus. an apparently harmless virus that already exists in most people. to deliver RPE65 to a small area of the retina.

The subjects said the vision in their treated eyes was slightly improved in dim lighting conditions.

"The patients report seeing brighter areas and perhaps some images, but basically the message is that this treatment is fully safe," William W. Hauswirth, a professor of ophthalmology and member of the university's Powell Gene Therapy Center, said in a news release issued by the university.

No ill effects, other than routine post-surgical soreness, were reported.

"The study has partially restored vision in three young adults, and it demonstrates that gene therapy can be effective in treating human vision disease," Dr. Paul A. Sieving, director of the National Eye Institute, which supported the experiment, said in the same news release. "Many human diseases are inherited in families and result from mutations in single genes. These genetic conditions are particularly suited to potential treatment by gene therapy. This trial to treat vision loss from the condition of Leber congenital amaurosis is an important demonstration of proof of principle and shows that we are on the right track. We can now invest in further work to refine, and ultimately to expand, genetic treatment approaches."

A detailed examination of the therapy's effectiveness in the treated portion of the eye was expected to be published in an upcoming issue of the Proceedings of the National Academy of Sciences.

LCA2 affects about 2,000 people in the United States and is one of several incurable forms of blindness collectively known as retinitis pigmentosa, which in turn affects about 200,000 Americans.

More information

The Prevent Blindness America has more about retinitis pigmentosa .



-- Kevin McKeever



SOURCE: University of Florida, news release, September 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Music Therapy Improves Well-Being of Very Ill Patients
2. Safety study indicates gene therapy for blindness improves vision
3. New study finds that add-on therapy improves depressive symptoms in bipolar disorder
4. FDA approves first drug for Huntingtons disease
5. Light Stretching Improves Range of Joint Motion
6. The California Board of Registered Nursing Approves Affiliations for Nursing Program in Glendale, California
7. Free White Paper: Hospital Tests Patient Lift Technologies; Improves Quality of Care
8. Overcoming inhibitors of cell death improves cancer therapy efficacy
9. New study shows calcium significantly improves childrens bone health
10. Madrid Hospital Improves Employee Safety With Ekahau Wi-Fi RTLS
11. Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Louis, Missouri (PRWEB) , ... April 26, 2017 ... ... cost, quality and clinical outcomes, today released the podcast, “Make Plans for ... in bringing value-based payment into the physician's office and how physicians and other ...
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer ... with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. ... plan incentives to a patient’s remote health progress, empowering the patient to take direct ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Miami native and ... a dentist. , “I could have never imagined back in 1991 that this journey ... Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant dentistry ...
(Date:4/26/2017)... Pa. (PRWEB) , ... April ... ... division, which provides an agile ecosystem and domain expertise for sponsors and ... configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
Breaking Medicine Technology: